The frequency of the severe adverse events was as follows: hypertension (23.07%), systolic ventricular dysfunction, gamma glutamyl transpeptidase (GGT) increase, leukopenia, and lymphopenia (15.38%), followed by hypoxia, hypomagnesemia, pneumonitis, and pain (7.69%). This evidence concerns the gene GGTLC1 and pneumonitis.